PH12022552743A1 - Feline antibody variants - Google Patents

Feline antibody variants

Info

Publication number
PH12022552743A1
PH12022552743A1 PH1/2022/552743A PH12022552743A PH12022552743A1 PH 12022552743 A1 PH12022552743 A1 PH 12022552743A1 PH 12022552743 A PH12022552743 A PH 12022552743A PH 12022552743 A1 PH12022552743 A1 PH 12022552743A1
Authority
PH
Philippines
Prior art keywords
antibody variants
feline antibody
feline
relates
variants
Prior art date
Application number
PH1/2022/552743A
Other languages
English (en)
Inventor
Lisa Marie Bergeron
Henry Luis Campos
Original Assignee
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc
Publication of PH12022552743A1 publication Critical patent/PH12022552743A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PH1/2022/552743A 2020-04-17 2021-04-16 Feline antibody variants PH12022552743A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063011491P 2020-04-17 2020-04-17
PCT/US2021/027839 WO2021212084A1 (en) 2020-04-17 2021-04-16 Feline antibody variants

Publications (1)

Publication Number Publication Date
PH12022552743A1 true PH12022552743A1 (en) 2024-03-25

Family

ID=75870744

Family Applications (1)

Application Number Title Priority Date Filing Date
PH1/2022/552743A PH12022552743A1 (en) 2020-04-17 2021-04-16 Feline antibody variants

Country Status (17)

Country Link
US (2) US20240067730A1 (https=)
EP (1) EP4136109A1 (https=)
JP (1) JP2023522030A (https=)
KR (1) KR20230005158A (https=)
CN (1) CN115667300A (https=)
AU (1) AU2021257355A1 (https=)
BR (1) BR112022020631A2 (https=)
CA (1) CA3176434A1 (https=)
CL (2) CL2022002856A1 (https=)
CO (1) CO2022014684A2 (https=)
EC (1) ECSP22080858A (https=)
IL (1) IL297290A (https=)
MX (1) MX2022012793A (https=)
PE (1) PE20230348A1 (https=)
PH (1) PH12022552743A1 (https=)
TW (1) TW202204404A (https=)
WO (1) WO2021212084A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020002871A2 (pt) 2017-08-15 2020-07-28 Kindred Biosciences, Inc. variantes fc de igg para uso veterinário
US11542333B2 (en) 2019-01-03 2023-01-03 Invetx, Inc. Compositions for increasing half-life of a therapeutic agent in canines and methods of use
US11434276B2 (en) 2020-05-11 2022-09-06 Invetx, Inc. Polypeptides with altered binding to neonatal Fc receptor (FcRn) and methods of use
CN115702169A (zh) * 2020-06-10 2023-02-14 株式会社梅花治疗 包含促红细胞生成素多肽的融合蛋白
EP4178977A1 (en) 2020-07-10 2023-05-17 Invetx, Inc. Compositions for increasing half-life of a therapeutic agent in felines and methods of use
AR123645A1 (es) * 2020-09-29 2022-12-28 Zoetis Services Llc Variantes de anticuerpos felinos
WO2025166165A1 (en) * 2024-02-01 2025-08-07 Zoetis Services, Llc Compositions and methods for modifying antibody effector functions

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US5698762A (en) 1994-12-09 1997-12-16 Dauerman; Leonard Microwave-assisted pyrolysis of waste polyaromatic hydrocarbons
US20030031671A1 (en) 2001-08-01 2003-02-13 Sydney Welt Methods of treating colon cancer utilizing tumor-specific antibodies
KR20070057839A (ko) 2004-08-19 2007-06-07 제넨테크, 인크. 변경된 이펙터 기능을 갖는 폴리펩티드 변이체
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
DK1817340T3 (da) 2004-11-12 2012-08-13 Xencor Inc Fc-varianter med ændret binding til fcrn
RU2529951C2 (ru) * 2007-12-26 2014-10-10 Ксенкор, Инк. ВАРИАНТЫ Fc С ИЗМЕНЕННЫМ СВЯЗЫВАНИЕМ C FcRn
US9505829B2 (en) 2010-08-19 2016-11-29 Zoetis Belgium S.A. Anti-NGF antibodies and their use
US8790651B2 (en) 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
EP2859018B1 (en) 2012-06-06 2021-09-22 Zoetis Services LLC Caninized anti-ngf antibodies and methods thereof
WO2018156180A1 (en) * 2017-02-24 2018-08-30 Kindred Biosciences, Inc. Anti-il31 antibodies for veterinary use
CN113194984A (zh) * 2018-10-18 2021-07-30 金德雷德生物科学股份有限公司 兽用的与新生儿Fc受体(FcRn)结合改变的Fc变体
CN113227134A (zh) * 2018-12-05 2021-08-06 株式会社梅花治疗 抗体的Fc区变体

Also Published As

Publication number Publication date
EP4136109A1 (en) 2023-02-22
KR20230005158A (ko) 2023-01-09
CN115667300A (zh) 2023-01-31
CA3176434A1 (en) 2021-10-21
BR112022020631A2 (pt) 2022-11-29
AU2021257355A1 (en) 2022-11-03
US20250026834A1 (en) 2025-01-23
TW202204404A (zh) 2022-02-01
US20240067730A1 (en) 2024-02-29
CO2022014684A2 (es) 2022-11-08
CL2023003376A1 (es) 2024-04-19
WO2021212084A1 (en) 2021-10-21
PE20230348A1 (es) 2023-03-02
CL2022002856A1 (es) 2023-06-02
MX2022012793A (es) 2022-11-07
IL297290A (en) 2022-12-01
JP2023522030A (ja) 2023-05-26
ECSP22080858A (es) 2023-01-31

Similar Documents

Publication Publication Date Title
PH12022552743A1 (en) Feline antibody variants
PH12022552742A1 (en) Canine antibody variants
PH12020500671A1 (en) Antibodies specific for gucy2c and uses thereof
PH12019502273A1 (en) Immunoconjugates of an anti-pd-1 antibody with a mutant il-2 or with il-15
WO2022067233A3 (en) Canine antibody variants
PH12023550161A1 (en) Pharmaceutical composition and use thereof
MA53356B1 (fr) Formulations sous-cutanées d'anticorps anti-cd38 et leurs utilisations
JOP20220161A1 (ar) جسم مضاد لـ lilrb1 واستخداماته
MX2023008785A (es) Mutaciones en regiones constantes de anticuerpos caninos.
MX2023005896A (es) Variantes de anticuerpos bovinos.
MX2020003219A (es) Anticuerpos que tienen especificidad para btn2 y usos de los mismos.
MA44645B1 (fr) Traitement combiné d'un anticorps anti-cd20 avec un inhibiteur de bcl-2 et un inhibiteur de mdm2
MX2022011077A (es) Variantes de transglutaminasa.
CL2023001781A1 (es) Mutaciones en regiones constantes de anticuerpos felinos
ZA202106807B (en) Antibodies having specificity for btn2 and uses thereof
MX2023003694A (es) Variantes de anticuerpos felinos.
MX2023009549A (es) Compuestos y metodos para prolongar la vida media de biomoleculas.
MX2025001433A (es) Mutantes de anticuerpos bovinos
MX2025002522A (es) Mutantes de anticuerpos porcinos
CO2018006345A2 (es) Almidón estabilizado
MX2024013189A (es) Anticuerpos anti-ly6e, inmunoconjugados y usos de estos
FR3035664B1 (fr) Utilisation de cysteine endoprotease pour diminuer le trouble de boissons
UA90682C2 (en) Variant fc regions